Insider Transactions
Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
---|---|---|---|---|---|---|---|
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 46,777 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 160,244 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 95,346 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 64,277 |
Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
May 14, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 525 | $3.07 | 311,934 |
May 14, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Other acquisition or disposition | -- | -- | 6,250 |
May 14, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Form 4 | Open market or private sale of non-derivative or derivative security | 2,250 | $3.07 | 406,879 |
May 14, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Form 4 | Other acquisition or disposition | -- | -- | 14,139 |
May 13, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 434 | $3.09 | 312,459 |
May 13, 2021 |
EVP, COO & CCO
|
EVP, COO & CCO | Form 4 | Open market or private sale of non-derivative or derivative security | 3,402 | $3.09 | 409,129 |
Apr 07, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | $3.15 | 145,967 |
Apr 06, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 1,025 | $3.24 | 350,867 |
Apr 06, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Other acquisition or disposition | -- | -- | 7,226 |
Apr 05, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 1,125 | $3.31 | 351,892 |
Apr 01, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 2,200 | $3.30 | 312,893 |
Apr 01, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Other acquisition or disposition | -- | -- | 6,250 |
Mar 31, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 1,739 | $3.20 | 315,093 |
Mar 17, 2021 |
EVP & Chief Financial Officer
|
EVP & Chief Financial Officer | Form 4 | Other acquisition or disposition | -- | -- | 11,840 |
Mar 17, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Other acquisition or disposition | -- | -- | 7,226 |
Mar 17, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Other acquisition or disposition | -- | -- | 6,250 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.